The HDAP HIV Drug Resistance Assay Reimbursement program provides direct reimbursement to healthcare sites for the cost of genotype and virtual phenotype testing for their uninsured HIV-positive patients.
Drug resistance testing is an important tool to measure whether a person’s virus is resistant to antiviral medications. With the help of genotype and phenotype testing, physicians can make an informed and individualized decision as to what antiretroviral therapies can be most effective for each of their patients.
To enroll in the HIV Drug Resistance Assay Reimbursement program, interested healthcare sites can contact HDAP staff. We will make arrangements with a laboratory service for reimbursement for viral resistance tests.
For more information on HIV Drug Resistance Testing reimbursement, our pharmacy program, or other client services please contact Craig Wells, Deputy Executive Director/HDAP Program Director, at 617.502.1734 or email@example.com, or call CRI’s main number at 617.502.1700.